EX-FILING FEES

Please wait

Calculation of Filing Fee Tables
S-4
REPLIGEN CORP

Table 1: Newly Registered and Carry Forward Securities	☐Not Applicable

		Security Type	Security Class Title	Fee Calculation or Carry Forward Rule	Amount Registered	Proposed Maximum Offering Price Per Unit	Maximum Aggregate Offering Price	Fee Rate	Amount of Registration Fee	Carry Forward Form Type	Carry Forward File Number	Carry Forward Initial Effective Date	Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward
Newly Registered Securities
Fees to be Paid	1	Equity	Common Stock (par value of $0.01 per share)	Other	7,277,203		$ 1,202,605,685.54	0.0001381	$ 166,079.85
Fees Previously Paid
Carry Forward Securities
Carry Forward Securities
			Total Offering Amounts:				$ 1,202,605,685.54		$ 166,079.85
			Total Fees Previously Paid:						$ 0.00
			Total Fee Offsets:						$ 0.00
			Net Fee Due:						$ 166,079.85

Offering Note

	Amount of Securities to be Received or Cancelled	Value per Share of Securities to be Received or Cancelled	Total Value of Securities to be Received or Cancelled	Cash Consideration Received by the registrant	Cash Consideration (Paid) by the registrant	Maximum Aggregate Offering Price
¹	Rule 457(f) Fee Calculation Details (1) This registration statement relates to the registration of the maximum number of shares of common stock, par value $0.01 per share, of the registrant ("Repligen common stock") estimated to be issuable by the registrant pursuant to the merger described in this registration statement and the Agreement and Plan of Merger, dated as of July 21, 2026 (the "merger agreement"), by and among the registrant, BioLife Solutions, Inc. ("BioLife") and Bravo Merger Sub, Inc. (2) Represents the maximum number of shares of Repligen common stock estimated to be issuable at the effective time of the merger. The number of shares of Repligen common stock, par value $0.01 per share, being registered is based on (a) (i) 48,924,156 shares of BioLife common stock issued and outstanding, including restricted stock awards, (ii) 1,096,820 shares of BioLife common stock subject to outstanding restricted stock unit awards, (iii) 430,062 shares of BioLife common stock subject to outstanding performance-based restricted stock unit awards, assuming target achievement, and (iv) 15,000 shares of BioLife common stock subject to outstanding stock options, with a weighted-average exercise price of $4.43 per share, multiplied by (b) the exchange ratio of 0.1442 of a share of Repligen common stock for each share of BioLife common stock entitled to receive Repligen common stock in the merger. Pursuant to the merger agreement, if the aggregate number of shares of Repligen common stock to be issued in connection with the merger (including the number of shares of Repligen common stock issuable in respect of the portion of the unallocated share reserve under BioLife's equity plans that Repligen determines to assume) would exceed the maximum number of shares of Repligen common stock that may be issued in connection with the transactions without requiring approval of Repligen's stockholders under Nasdaq Listing Rule 5635, which number shall not exceed 19.9% of the issued and outstanding shares of Repligen common stock immediately prior to the effective time of the merger (the "Maximum Share Number"), then (i) the exchange ratio will be reduced to the minimum extent necessary, rounded down to four decimal places, so that the aggregate stock consideration does not exceed the Maximum Share Number and (ii) the cash consideration will be increased on a per-share basis by an amount equal to (A) the volume-weighted average trading price of one share of Repligen common stock on Nasdaq for the five consecutive trading days ending two trading days immediately preceding the effective time of the merger, multiplied by (B) the difference between the exchange ratio before and after such adjustment, with such amount rounded up to the nearest whole cent. (3) Estimated solely for the purpose of calculating the registration fee required by Section 6(b) of the Securities Act and calculated in accordance with Rules 457(c), 457(f)(1) and 457(f)(3) under the Securities Act, based on (i) the market value of the estimated maximum number of shares of BioLife common stock that may be canceled and exchanged in the merger (as set forth in the preceding footnote), as established by the average of the high and low sales prices of BioLife common stock on the Nasdaq Global Select Market on August 8, 2026 of $35.08, minus (ii) $567,742,927.50, which is the aggregate amount of cash estimated to be paid by Repligen to BioLife stockholders in the merger. The aggregate amount of cash set forth in clause (ii) of the prior sentence is equal to the product obtained by multiplying (A) $11.25 by (B) the estimated maximum BioLife shares.
	50,466,038	$ 35.08	$ 1,770,348,613.04		$ 567,742,927.50	$ 1,202,605,685.54

Table 2: Fee Offset Claims and Sources	☑Not Applicable

		Registrant or Filer Name	Form or Filing Type	File Number	Initial Filing Date	Filing Date	Fee Offset Claimed	Security Type Associated with Fee Offset Claimed	Security Title Associated with Fee Offset Claimed	Unsold Securities Associated with Fee Offset Claimed	Unsold Aggregate Offering Amount Associated with Fee Offset Claimed	Fee Paid with Fee Offset Source
Rules 457(b) and 0-11(a)(2)
Fee Offset Claims
Fee Offset Sources
Rule 457(p)
Fee Offset Claims
Fee Offset Sources

Table 3: Combined Prospectuses	☑Not Applicable

	Security Type	Security Class Title	Amount of Securities Previously Registered	Maximum Aggregate Offering Price of Securities Previously Registered	Form Type	File Number	Initial Effective Date